Hims & Hers Health board approves $250 million share repurchase program

Hims & Hers Health, Inc. (HIMS) has announced a new $250 million share repurchase program, effective until November 2028, following the complete utilization of its prior $100 million buyback initiative, signaling a continued focus on returning capital to shareholders. Concurrently, the company appointed Deb Autor as its first Chief Policy Officer and launched 'Labs,' a new service offering blood tests and health monitoring. Truist Securities reiterated a Hold rating on HIMS with a $37 price target, acknowledging strategic developments including changes to the company's weight loss patient intake process and a partnership with Klarna.

Analysis

Hims & Hers Health (HIMS) has authorized a new $250 million share repurchase program, extending until November 2028. This follows the complete utilization of its previous $100 million program, which saw the repurchase of 1,334,572 shares for $55.5 million between October 1 and November 7, 2025. This aggressive capital return strategy underscores management's confidence in the company's valuation and commitment to enhancing shareholder value.

The company is actively expanding its service offerings and strategic partnerships. Key developments include the launch of "Labs," a new service providing accessible blood tests and health monitoring, and a partnership with Klarna for payment plans to improve patient access to weight loss programs. These initiatives aim to broaden HIMS's healthcare ecosystem and address evolving consumer needs in preventive and personalized health.

HIMS has also strengthened its governance with the appointment of Deb Autor as its first Chief Policy Officer, signaling a proactive approach to regulatory engagement. Despite these strategic moves, Truist Securities maintains a "Hold" rating with a $37 price target, suggesting a neutral near-term outlook while acknowledging the company's ongoing developments. The overall sentiment surrounding these announcements is strongly positive, with a HIMS-specific sentiment score of 0.8.

Key Decisions for Investors

• Monitor the execution of the new $250 million share repurchase program for its impact on EPS and stock valuation, especially given the prior program's full utilization.
• Evaluate the market reception and adoption rates of the new "Labs" service and the Klarna partnership, as these represent key growth vectors and potential revenue diversification for HIMS.
• Consider the implications of the "Hold" rating from Truist Securities against the strongly positive market sentiment, assessing whether current valuation adequately reflects the company's strategic expansion and capital return initiatives.